This article was based on results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project, supported with US Federal funds from the National Institute of Mental Health (NIMH) under contract NO1 MH90001. The aim of this project was to examine the comparative effectiveness of antipsychotic drugs in conditions for which their use is clinically indicated, including schizophrenia and Alzheimer's disease. The project was carried out by principal investigators from the University of North Carolina, Duke University, the University of Southern California, the University of Rochester and Yale University in association with Quintiles, Inc.; the program staff of the Division of Interventions and Services Research of the NIMH; and investigators from 56 sites in the USA (CATIE Study Investigators Group). AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Forest Pharmaceuticals, Inc., Janssen Pharmaceutica Products, L.P., Eli Lilly and Company, Otsuka Pharmaceutical Co., Ltd., Pfizer, Inc., and Zenith Goldline Pharmaceuticals, Inc., provided medications for the studies. This work was also supported by the Foundation of Hope of Raleigh, North Carolina. The CATIE Study Investigators Group includes Lawrence Adler, MD, Clinical Insights; Mohammed Bari, MD, Synergy Clinical Research; Irving Belz, MD, Tri-County/MHMR; Raymond Bland, MD, SIU School of Medicine; Thomas Blocher, MD, MHMRA of Harris County; Brent Bolyard, MD, Cox North Hospital; Alan Buffenstein, MD, The Queen's Medical Center; John Burruss, MD, Baylor College of Medicine; Matthew Byerly, MD, University of Texas Southwestern Medical Center at Dallas; Jose Canive, MD, Albuquerque VA Medical Center; Stanley Caroff, MD, Behavioral Health Service; Charles Casat, MD, Behavioral Health Center; Eugenio Chavez-Rice, MD, El Paso Community MHMR Center; John Csernansky, MD, Washington University School of Medicine; Pedro Delgado, MD, University Hospitals of Cleveland; Richard Douyon, MD, VA Medical Center; Cyril D'Souza, MD, Connecticut Mental Health Center; Ira Glick, MD, Stanford University School of Medicine; Donald Goff, MD, Massachusetts General Hospital; Silvia Gratz, MD, Eastern Pennsylvania Psychiatric Institute; George T. Grossberg, MD, St Louis University School of Medicine – Wohl Institute; Mahlon Hale, MD, New Britain General Hospital; Mark Hamner, MD, Medical University of South Carolina and Veterans Affairs Medical Center; Richard Jaffe, MD, Belmont Center for Comprehensive Treatment; Dilip Jeste, MD, University of California-San Diego, VA Medical Center; Anita Kablinger, MD, Louisiana State University Health Sciences Center; Ahsan Khan, MD, Psychiatric Research Institute; Steven Lamberti, MD, University of Rochester Medical Center; Michael T. Levy, MD, PC, Staten Island University Hospital; Jeffrey Lieberman, MD, University of North Carolina at Chapel Hill; Gerald Maguire, MD, University of California Irvine; Theo Manschreck, MD, Corrigan Mental Health Center; Joseph McEvoy, MD, Duke University Medical Center; Mark McGee, MD, Appalachian Psychiatric Healthcare System; Herbert Meltzer, MD, Vanderbilt University Medical Center; Alexander Miller, MD, University of Texas Health Science Center at San Antonio; Del D. Miller, MD, University of Iowa; Henry Nasrallah, MD, University of Cincinnati Medical Center; Charles Nemeroff, MD, PhD, Emory University School of Medicine; Stephen Olson, MD, University of Minnesota Medical School; Gregory F. Oxenkrug, MD, St. Elizabeth's Medical Center; Jayendra Patel, MD, University of Mass Health Care; Frederick Reimherr, MD, University of Utah Medical Center; Silvana Riggio, MD, Mount Sinai Medical Center-Bronx VA Medical Center; Samuel Risch, MD, University of California-San Francisco; Bruce Saltz, MD, Henderson Mental Health Center; Thomas Simpatico, MD, Northwestern University; George Simpson, MD, University of Southern California Medical Center; Michael Smith, MD, Harbor - UCLA Medical Center; Roger Sommi, PharmD, University of Missouri; Richard M. Steinbook, MD, University of Miami School of Medicine; Michael Stevens, MD, Valley Mental Health; Andre Tapp, MD, VA Puget Sound Health Care System; Rafael Torres, MD, University of Mississippi; Peter Weiden, MD, SUNY Downstate Medical Center; James Wolberg, MD, Mount Sinai Medical Center. The study was also supported by the National Institute of Mental Health through an Independent Research Scientist Career Award to J.S.
Walsh, E, Buchanan, A, Fahy, T. Violence and schizophrenia: examining the evidence. Br J Psychiatry
2002; 180: 490–5.
Swanson, JW, Swartz, MS, Elbogen, EB. Effectiveness of atypical antipsychotic medications in reducing violent behavior among persons with schizophrenia in community-based treatment. Schizophr Bull
2004; 30: 3–20.
Buckley, PF. The role of typical and atypical antipsychotic medications in the management of agitation and aggression. J Clin Psychiatry
1999; 60: 52–60.
Buckley, PF, Bartell, J, Donenwirth, K, Lee, S, Torigoe, F, Schulz, SC. Violence and schizophrenia: clozapine as a specific antiaggressive agent. Bull Am Acad Psychiatry Law
1995; 23: 607–11.
Citrome, L, Krakowski, M, Greenberg, WM, Andrade, E, Volavka, J. Antiaggressive effect of quetiapine in a patient with schizoaffective disorder. J Clin Psychiatry
2001; 62: 901.
Taylor, PJ, Butwell, M, Gray, C, Daly, R, Delal, B, Ferraro, D, Gibb, R, Heads, T, Huckstep, B, Larkin, E, Leese, M, Shetty, G, Winton, M, Tidmarsh, D, Williams, D. Schizophrenia, violence, clozapine and risperidone: a review. Br J Psychiatry
1996; 169: 21–30.
Volavka, J. The effects of clozapine on aggression and substance abuse in schizophrenic patients. J Clin Psychiatry
1999; 60: 43–6.
Volavka, J, Czobor, P, Sheitman, B, Lindenmayer, JP, Citrome, L, McEvoy, JP, Cooper, TB, Chakos, M, Lieberman, JA. Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder. Am J Psychiatry
2002; 159: 255–62.
Lieberman, JA, Stroup, TS, McEvoy, JP, Swartz, MS, Rosenheck, RA, Perkins, DO, Keefe, RS, Davis, SM, Davis, CE, Lebowitz, BD, Severe, J, Hsiao, JK. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med
2005; 353: 1209–23.
Jones, PB, Barnes, TRE, Davies, L, Dunn, G, Lloyd, H, Hayhurst, KP, Murray, RM, Markwick, A, Lewis, SW. Randomized controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry
2006; 63: 1079–87.
Tiihonen, J, Walhbeck, K, Lonnqvist, J, Klaukka, T, loannidis, JP, Volavka, J, Haukka, J. Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalisation due to schizophrenia and schizoaffective disorder: observational follow-up study. BMJ
2006; 333: 224–7.
Swanson, JW, Van Dorn, RA, Swartz, MS, Smith, A, Elbogen, EB, Monahan, J. Alternative pathways to violence in persons with schizophrenia: the role of childhood antisocial behavior problems. Law Hum Behav, .
Swanson, JW, Swartz, MS, Van Dorn, RA, Elbogen, EB, Wagner, HR, Rosenheck, RA, Stroup, TS, McEvoy, JP, Lieberman, JA. A national study of violent behavior in persons with schizophrenia. Arch Gen Psychiatry
2006; 63: 490–9.
Steadman, HJ, Mulvey, EP, Monahan, J, Robbins, PC, Appelbaum, PS, Grisso, T, Roth, LH, Silver, E. Violence by people discharged from acute psychiatric inpatient facilities and by others in the same neighborhoods. Arch Gen Psychiatry
1998; 55: 393–401.
Swanson, JW, Swartz, MS, Elbogen, EB, Van Dorn, RA. Reducing violence risk in persons with schizophrenia: olanzapine vs. risperidone. J Clin Psychiatry
2004; 65: 1666–73.
Stroup, TS, McEvoy, JP, Swartz, MS, Byerly, MJ, Glick, ID, Canive, JM, McGee, MF, Simpson, GM, Stevens, MC, Lieberman, JA. The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development. Schizophr Bull
2003; 29: 15–31.
Monahan, J, Steadman, H (eds). Violence and Mental Disorder: Developments in Risk Assessment.
University of Chicago Press, 1994.
Link, BG, Stueve, A, Phelan, J. Psychotic symptoms and violent behaviors: probing the components of ‘threat/control override’ symptoms. Soc Psychiatry Psychiatr Epidemiol
1998; 33: s55–60.
Swanson, J, Estroff, S, Swartz, M, Borum, R, Lachicotte, W, Zimmer, C, Wagner, R. Violence and severe mental disorder in clinical and community populations: the effects of psychotic symptoms, comorbidity, and lack of treatment. Psychiatry
1997; 60: 1–22.
Farrington, DP, Loeber, R. Some benefits of dichotomization in psychiatric and criminological research. Crim Behav Ment Health
2000; 10: 100–22.
George, L, Blazer, D, Hughes, D, Fowler, N. Social support and the outcomes of major depression. Br J Psychiatry
1989; 186: 651–6.
First, MB, Spitzer, RL, Gibbon, M, Williams, JBW. Structured Clinical Interview for Axes I and II DSM–IV Disorders – Patient Edition (SCID–I/P).
Biometrics Research Department, New York State Psychiatric Institute, 1996.
Guy, W. Early Clinical Drug Evaluation (ECDEU) Assessment Manual.
National Institute of Menta Health, 1976.
Kay, SR, Fiszbein, A, Opler, LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull
1987; 13: 261–76.
Addington, D, Addington, J, Schissel, B. A depression rating scale for schizophrenics. Schizophr Res
1990; 3: 247–51.
McEvoy, JP, Aland, JJ, Wilson, WH, Guy, W, Hawkins, L. Measuring chronic schizophrenic patients attitudes toward their illness and treatment. Hosp Community Psychiatry
1981; 32: 856–8.
Swartz, MS, Wagner, HR, Swanson, JW, Stroup, TS, McEvoy, JP, Canive, JM, Miller, DD, Reimherr, F, McGee, M, Khan, A, Van Dorn, R, Rosenheck, RA, Lieberman, JA. Substance use in persons with schizophrenia: baseline prevalence and correlates from the NIMH CATIE study. J Nerv Ment Dis
2006; 194: 164–72.
Heinrichs, DW, Hanlon, ET, Carpenter, WT. The quality of life scale: an instrument for rating the schizophrenic deficit syndrome. Schizophr Bull
1984; 10: 388–98.
Fleiss, JL, Williams, JB, Dubro, AF. The logistic regression analysis of psychiatric data. J Psychiatr Res
1986; 20: 145–209.
Hosmer, D, Lemeshow, S. Applied Logistic Regression (2nd edn). Wiley, 2000.
Snijders, TAB, Bosker, RJ. Multilevel Analysis: An Introduction to Basic and Advanced Multilevel Modeling.
Swanson, JW. Mental disorder, substance abuse, and community violence: an epidemiological approach. In Violence and Mental Disorder: Developments in Risk Assessment (eds Monahan, J, Steadman, H): 101–36. University of Chicago Press, 1994.
Wallace, C, Mullen, PE, Burgess, P. Criminal offending in schizophrenia over a 25-year period marked by deinstitutionalization and increasing prevalence of comorbid substance use disorders. Am J Psychiatry
2004; 161: 716–27.
Hiday, VA, Swanson, JW, Swartz, MS, Borum, R, Wagner, HR. Victimization: a link between mental illness and violence?
Int J Law Psychiatry
2001; 24: 559–72.
Link, BG, Stueve, A. Psychotic symptoms and the violent/illegal behavior of mental patients compared to community controls. In Violence and Mental Disorder: Developments in Risk Assessment (eds Monahan, J, Steadman, H): 137–160. University of Chicago Press, 1994.
Mullen, PE. Schizophrenia and violence: from correlations to preventive strategies. Advan Psychiatr Treat
2006; 12: 239–48.
Swanson, JW, Borum, R, Swartz, MS, Monahan, J. Psychotic symptoms and disorders and the risk of violent behavior in the community. Crim Behav Ment Health
1996; 6: 317–38.
Swanson, JW, Swartz, MS, Essock, SM, Osher, FC, Wagner, HR, Goodman, LA, Rosenberg, SD, Meador, KG. The social-environmental context of violent behavior in persons treated for severe mental illness. Am J Publ Health
2002; 92: 1523–31.
Appelbaum, PS, Robbins, PC, Monahan, J. Violence and delusions: data from the MacArthur Violence Risk Assessment Study. Am J Psychiatry
2000; 157: 566–72.
Herrera, JN, Sramek, JJ, Costa, JF, Roy, S, Heh, CW, Nguyen, BN. High potency neuroleptics and violence in schizophrenics. J Nerv Ment Dis
1988; 176: 558–61.
Krakowski, MI, Czobor, P, Citrome, L, Bark, N, Cooper, TB. Atypical antipsychotic agents in the treatment of violent patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry
2006; 63: 622–9.
Volavka, J, Czobor, P, Nolan, K, Sheitman, B, Lindenmayer, JP, Citrome, L, McEvoy, JP, Cooper, TB, Lieberman, JA. Overt aggression and psychotic symptoms in patients with schizophrenia treated with clozapine, olanzapine, risperidone, or haloperidol. J Clin Psychopharmacol
2004; 24: 225–8.
Nolan, KA, Volavka, J, Mohr, P, Czobor, P. Psychopathy and violent behavior among patients with schizophrenia or schizoaffective disorder. Psychiatr Serv
1999; 50: 787–92.